CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance
Authors:
- Giovanni CarulliGiovanni Carulli
- Gabriele BudaGBGabriele Buda
- Antonio AzzaràAAAntonio Azzarà
- Eugenio M. CianciaECEugenio M. Ciancia
- Paola SammuriPSPaola Sammuri
- Cristiana DomenichiniCDCristiana Domenichini
- Valentina GuerriVGValentina Guerri
- Mario PetriniMPMario Petrini
- 15 August 2015
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 135 (1) , 11-14
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Profile of elotuzumab and its potential in the treatment of multiple myelomaBlood and Lymphatic Cancer: Targets and Therapy, 2014
- Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseasesLeukemia Research, 2014
- Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myelomaHaematologica, 2011
- SLAM Family Receptors and SAP Adaptors in ImmunityAnnual Review of Immunology, 2011
- Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cellsImmunology Letters, 2011
- Multiple myelomaAnnals of Oncology, 2010
- Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histologyCytometry Part B: Clinical Cytometry, 2010
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disordersHaematologica, 2008
- International uniform response criteria for multiple myelomaLeukemia, 2006